Korean biosimilars' golden decade

Samsung Bioepis' Pyzchiva (Stelara equivalent) cracked U.S. top-3 ustekinumab market in one year. Celltrion's Steqeyma gains via Costco. Global pharma M&A races to bag biosimilar firms ahead of blockbuster patent cliffs.